R&D, Innovation and Competitiveness in the European Chemical Industry

Abstract

Preface. Introduction F. Cesaroni, A. Gambardella, W. Garcia-Fontes. 1. Objective. 2. How this book is organised. 3. Policy concerns. 4. References. 1: Market Structure and Innovation. Market structure, competition and innovation in the European and US chemical industries P.L. Marin, G. Siotis. 1. Introduction. 2. Theoretical motivation. 3. Data and variables from the chemical industry. 4. Empirical findings. 5. Conclusions. 6. References. Mergers and acquisitions in the chemical industry: similarities and dissimilarities across the Atlantic C. Ornaghi, P.L. Marin, G. Siotis. 1. Introduction. 2. Data. 3. Overview of M&As flows. 4. Analysis of investment flows by sector. 5. Diversification strategies. 6. Conclusions. 7. References. Corporate restructuring and R&D: a panel data analysis for the chemical industry A. Arora, M. Ceccagnoli, M. Da Rin. 1. Introduction. 2. Data description. 3. R&D and corporate restructuring. 4. Conclusions. 5. References. 2: Technology Development and Diffusion. Watching paint dry? S. Brusoni. 1. Introduction. 2. Some definitions. 3. Industry structure in the 1990s. 4. Innovation: sources, trends and appropriability. 5. Environmentalregulation and innovation. 6. The development of low solvents and solvent-free coatings. 7. The adoption of waterborne formulations. 8. Discussionsand conclusions. 9. References. Research collaborations among inventors and the location of R&D in the European Chemical Industry M. Mariani. 1. Introduction. 2. Organisational vs. geographical proximity. 3. Insights from the data. 4. Multiple correlations: probit and OLS regressions. 5. Conclusions. 6. Main references. 7. Annex. Collaboration between a research university and firms and other institutions A. Geuna, P. Llerena, M. Matt, M. Savona. 1. Introduction. 2. University-industry relationships: the core topics. 3. ULP contractual relationships. 4. Characteristics of chemistry domain contracts. 5. Entry, exit and persistence of collaboration. 6. Conclusions. 7. References. The nature and extent of the market for technology in biopharmaceuticals A. Arora, A. Gambardella, F. Pammolli, M. Riccaboni. 1. Introduction. 2. The sample of drug R&D products. 3. The NBFs as an American phenomenon. 4. 'Risky' projects. 5. Probability of success: licensed vs. in-house products. 6. Assessing development capabilities. 7. Assessing the originators capabilities. 8. Failing at earlier stages. 9. Conclusions. 10. Appendix. 11. References. 3: Policy Regulation an